Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,134 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CCNE1 copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models.
Xu H, George E, Kinose Y, Kim H, Shah JB, Peake JD, Ferman B, Medvedev S, Murtha T, Barger CJ, Devins KM, D'Andrea K, Wubbenhorst B, Schwartz LE, Hwang WT, Mills GB, Nathanson KL, Karpf AR, Drapkin R, Brown EJ, Simpkins F. Xu H, et al. Among authors: mills gb. Cell Rep Med. 2021 Sep 23;2(9):100394. doi: 10.1016/j.xcrm.2021.100394. eCollection 2021 Sep 21. Cell Rep Med. 2021. PMID: 34622231 Free PMC article.
Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo.
Simpkins F, Hevia-Paez P, Sun J, Ullmer W, Gilbert CA, da Silva T, Pedram A, Levin ER, Reis IM, Rabinovich B, Azzam D, Xu XX, Ince TA, Yang JY, Verhaak RG, Lu Y, Mills GB, Slingerland JM. Simpkins F, et al. Among authors: mills gb. Clin Cancer Res. 2012 Nov 1;18(21):5911-23. doi: 10.1158/1078-0432.CCR-12-1257. Epub 2012 Aug 15. Clin Cancer Res. 2012. PMID: 22896656 Free PMC article.
A functional genomic approach identifies FAL1 as an oncogenic long noncoding RNA that associates with BMI1 and represses p21 expression in cancer.
Hu X, Feng Y, Zhang D, Zhao SD, Hu Z, Greshock J, Zhang Y, Yang L, Zhong X, Wang LP, Jean S, Li C, Huang Q, Katsaros D, Montone KT, Tanyi JL, Lu Y, Boyd J, Nathanson KL, Li H, Mills GB, Zhang L. Hu X, et al. Among authors: mills gb. Cancer Cell. 2014 Sep 8;26(3):344-357. doi: 10.1016/j.ccr.2014.07.009. Cancer Cell. 2014. PMID: 25203321 Free PMC article.
MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer.
Hew KE, Miller PC, El-Ashry D, Sun J, Besser AH, Ince TA, Gu M, Wei Z, Zhang G, Brafford P, Gao W, Lu Y, Mills GB, Slingerland JM, Simpkins F. Hew KE, et al. Among authors: mills gb. Clin Cancer Res. 2016 Feb 15;22(4):935-47. doi: 10.1158/1078-0432.CCR-15-0534. Epub 2015 Oct 19. Clin Cancer Res. 2016. PMID: 26482043 Free PMC article.
Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.
Krepler C, Xiao M, Sproesser K, Brafford PA, Shannan B, Beqiri M, Liu Q, Xu W, Garman B, Nathanson KL, Xu X, Karakousis GC, Mills GB, Lu Y, Ahmed TA, Poulikakos PI, Caponigro G, Boehm M, Peters M, Schuchter LM, Weeraratna AT, Herlyn M. Krepler C, et al. Among authors: mills gb. Clin Cancer Res. 2016 Apr 1;22(7):1592-602. doi: 10.1158/1078-0432.CCR-15-1762. Epub 2015 Dec 16. Clin Cancer Res. 2016. PMID: 26673799 Free PMC article.
Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis.
Rupaimoole R, Lee J, Haemmerle M, Ling H, Previs RA, Pradeep S, Wu SY, Ivan C, Ferracin M, Dennison JB, Millward NMZ, Nagaraja AS, Gharpure KM, McGuire M, Sam N, Armaiz-Pena GN, Sadaoui NC, Rodriguez-Aguayo C, Calin GA, Drapkin RI, Kovacs J, Mills GB, Zhang W, Lopez-Berestein G, Bhattacharya PK, Sood AK. Rupaimoole R, et al. Among authors: mills gb. Cell Rep. 2015 Dec 22;13(11):2395-2402. doi: 10.1016/j.celrep.2015.11.047. Epub 2015 Dec 10. Cell Rep. 2015. PMID: 26686630 Free PMC article.
Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics.
Liu JF, Palakurthi S, Zeng Q, Zhou S, Ivanova E, Huang W, Zervantonakis IK, Selfors LM, Shen Y, Pritchard CC, Zheng M, Adleff V, Papp E, Piao H, Novak M, Fotheringham S, Wulf GM, English J, Kirschmeier PT, Velculescu VE, Paweletz C, Mills GB, Livingston DM, Brugge JS, Matulonis UA, Drapkin R. Liu JF, et al. Among authors: mills gb. Clin Cancer Res. 2017 Mar 1;23(5):1263-1273. doi: 10.1158/1078-0432.CCR-16-1237. Epub 2016 Aug 29. Clin Cancer Res. 2017. PMID: 27573169 Free PMC article.
A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers.
George E, Kim H, Krepler C, Wenz B, Makvandi M, Tanyi JL, Brown E, Zhang R, Brafford P, Jean S, Mach RH, Lu Y, Mills GB, Herlyn M, Morgan M, Zhang X, Soslow R, Drapkin R, Johnson N, Zheng Y, Cotsarelis G, Nathanson KL, Simpkins F. George E, et al. Among authors: mills gb. JCI Insight. 2017 Jan 12;2(1):e89760. doi: 10.1172/jci.insight.89760. JCI Insight. 2017. PMID: 28097235 Free PMC article.
A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma.
Krepler C, Sproesser K, Brafford P, Beqiri M, Garman B, Xiao M, Shannan B, Watters A, Perego M, Zhang G, Vultur A, Yin X, Liu Q, Anastopoulos IN, Wubbenhorst B, Wilson MA, Xu W, Karakousis G, Feldman M, Xu X, Amaravadi R, Gangadhar TC, Elder DE, Haydu LE, Wargo JA, Davies MA, Lu Y, Mills GB, Frederick DT, Barzily-Rokni M, Flaherty KT, Hoon DS, Guarino M, Bennett JJ, Ryan RW, Petrelli NJ, Shields CL, Terai M, Sato T, Aplin AE, Roesch A, Darr D, Angus S, Kumar R, Halilovic E, Caponigro G, Jeay S, Wuerthner J, Walter A, Ocker M, Boxer MB, Schuchter L, Nathanson KL, Herlyn M. Krepler C, et al. Among authors: mills gb. Cell Rep. 2017 Nov 14;21(7):1953-1967. doi: 10.1016/j.celrep.2017.10.021. Cell Rep. 2017. PMID: 29141225 Free PMC article.
1,134 results